CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.

Megan V Yanik Michael E SeifertJayme E LockeVera Hauptfeld-DolejsekMichael R CrowleyGary R CutterRoslyn B MannonDaniel I FeigNita A Limdi

Published in: Pediatric transplantation (2019)

Pediatric kidney transplant recipients with the CYP3A5*1 allele (expressers) take a longer time to achieve therapeutic TAC levels than those with the CYP3A5*3 allele (non-expressers). However, we observed no significant differences in acute rejection or CNI nephrotoxicity based on CYP3A5 genotype. Thus CYP3A5 genotype was not observed to have an immediate impact on early transplant outcomes.

Keyphrases

liver failure
drug induced
metabolic syndrome
skeletal muscle
aortic dissection